Alexandra Díaz-Alba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandra Díaz-Alba has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Marco Antonio Rodríguez-Florido
Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguto Social, Mexico City, Mexico
2 shared publications - Alberto González-Aguilar
Neuro-oncology Department, Centro Médico Naval, Mexico City, Mexico
1 shared publication - Alejandro Rodríguez-Camacho
Radioneurosurgery Unit, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City 14269, Mexico
1 shared publication - Bernardo Cacho-Díaz
Unidad de Neuro-oncologia, Instituto Nacional de Cancerologia, Mexico City, Mexico
1 shared publication - Carlos Axel López-Pérez
Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Zapopan 45201, Mexico
1 shared publication - Enrique Caballe-Perez
Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico
1 shared publication
Latest Publications
- 13 August 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 175 (3) , 1227-1234
Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period
Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases. A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024. From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies. In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.
- 13 August 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 175 (3) , 1227-1234
Real-world experience outcome in patients with central nervous system metastases: information on 2,226 patients during a 15-year period
Most data regarding Central nervous system (CNS) metastases are derived from non-Hispanic populations enrolled in clinical trials. This study aims to characterize the primary tumors, initial treatments, and outcomes in a Hispanic/Latino real-world population with CNS metastases. A retrospective analysis of a multicenter cohort of patients with CNS metastases treated from 2010 to 2024. From 2,261 patients with CNS metastases, 84% had brain metastases and 16% had neoplastic meningitis. The most common primary tumors were breast (40%), lung (27%), genitourinary (11%), gynecologic (6%), and melanoma (4%). Whole-brain radiotherapy and systemic therapy were initially prescribed in 84% and 55% of cases, respectively. The median overall survival was 9.8 months (95% CI, 8.9 - 10.7). Variables associated with outcomes included location of the primary tumor, molecular subtype, type of CNS metastases (brain metastases vs. neoplastic meningitis), and access to targeted therapies. In a real-world cohort of Hispanic/Latino patients with CNS metastases, survival has remained poor over the past 15 years. This highlights the need for interventions and research to improve outcomes.
- 14 May 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 158 (3) , 369-378
Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity
Introduction Diffuse midline glioma (DMG) H3 K27-altered is a type of high-grade gliomas first recognized as a new entity in the 2016 World Health Organization Classification of Central Nervous System (CNS) Tumors as DMG H3 K27M-mutant, recently renamed in the new 2021 WHO classification. The aim of this review is to describe the characteristics of diffuse midline gliomas H3 K27-altered in the adult population. Methods We performed a review of the current literature regarding the genetic, clinical, imaging characteristics and management of diffuse midline gliomas H3 K27-altered in adult patients. Results The 2021 WHO classification now designates the previously recognized DMG H3K27M-mutant as DMG H3 K27-altered, recognizing the alternative mechanisms by which the pathogenic pathway can be altered. Thus, the diagnostic criteria for this entity consist of diffuse growth pattern, midline anatomic location, and H3 K27-specific neuroglial mutations. DMGs’ characteristic midline location makes them difficult to surgically resect and biopsy, carrying high mortality and morbidity rates, with median survival ranging from 9 to 12 months in adult patients. Conclusion The diagnosis of DMGs H3 K27-altered in adult patients should be considered upon neurological symptoms associated with an infiltrative midline brain tumor detected on imaging. Future studies are necessary to continue refining their characteristics in this age group.
- 14 May 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 158 (3) , 369-378
Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity
Introduction Diffuse midline glioma (DMG) H3 K27-altered is a type of high-grade gliomas first recognized as a new entity in the 2016 World Health Organization Classification of Central Nervous System (CNS) Tumors as DMG H3 K27M-mutant, recently renamed in the new 2021 WHO classification. The aim of this review is to describe the characteristics of diffuse midline gliomas H3 K27-altered in the adult population. Methods We performed a review of the current literature regarding the genetic, clinical, imaging characteristics and management of diffuse midline gliomas H3 K27-altered in adult patients. Results The 2021 WHO classification now designates the previously recognized DMG H3K27M-mutant as DMG H3 K27-altered, recognizing the alternative mechanisms by which the pathogenic pathway can be altered. Thus, the diagnostic criteria for this entity consist of diffuse growth pattern, midline anatomic location, and H3 K27-specific neuroglial mutations. DMGs’ characteristic midline location makes them difficult to surgically resect and biopsy, carrying high mortality and morbidity rates, with median survival ranging from 9 to 12 months in adult patients. Conclusion The diagnosis of DMGs H3 K27-altered in adult patients should be considered upon neurological symptoms associated with an infiltrative midline brain tumor detected on imaging. Future studies are necessary to continue refining their characteristics in this age group.